Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Zyden Gentec Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
3 users have voted
Option Chain
Analyzes market sentiment, predicts Zyden Gentec Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
No Records Found
Key fundamentals
Evaluate the intrinsic value of Zyden Gentec Ltd stock
| Name | March-14 | March-13 | March-12 | March-11 | March-10 |
|---|---|---|---|---|---|
| Assets | 17.776 | 19.6947 | 23.7729 | 18.6404 | 12.512 |
| Liabilities | 17.776 | 19.6947 | 23.7729 | 18.6404 | 12.512 |
| Equity | 11.1124 | 11.1124 | 11.1124 | 5.0674 | 5.0674 |
| Gross Profit | -1.3092 | -1.0163 | -2.9475 | 1.0934 | 1.2301 |
| Net Profit | -0.2649 | -0.7307 | -4.0997 | -0.108 | 0.123 |
| Cash From Operating Activities | 0.2593 | 3.6913 | -1.7757 | -1.6116 | 3.9822 |
| NPM(%) | -16.67 | -9.68 | -43.1 | -0.89 | 0.7 |
| Revenue | 1.5893 | 7.5488 | 9.5119 | 12.097 | 17.5198 |
| Expenses | 2.8985 | 8.5651 | 12.4595 | 11.0035 | 16.2897 |
| ROE(%) | -1.98 | -5.48 | -30.78 | -0.81 | 0.92 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Zyden Gentec Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 838.80 | -0.20 | 11.87 | 0.50 | 1321.50 | 1.37 |
| Lotus Eye Hospital and Institute Ltd | 81.54 | 3.08 | 339.00 | 1.81 | 14.01 | 0.61 |
| Bharat Immunological and Biologicals Corporation Ltd | 23.33 | 0.86 | 0.00 | 3.76 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 697.80 | -1.10 | 0.00 | 1.71 | -687.11 | 0.00 |
Company Info
1994 - The company was incorporated as a manufacturer of natural products and chemicals. 2004 - Members at the annual general meeting of the company had approved the increase in authorized share capital from Rs 4.5 crore to 7.5 crore. - The company had an agreement of understanding (AOU) with Zhejiang Hisun Pharmaceuticals Company Ltd. of China in the field of development and sales of anti cancer compounds, their intermediates and penultimates. 2005 - The company had signed an agreement of cooperation and agency with Allessa Chemie of Germany. - The company had planned to raise USD25 million through the issue of Foreign Currency Convertible Bonds (FCCBs). - The company had authorized its board to borrow up to Rs 250 crore. - The company had increased its authorized share capital from Rs 7.5 crore to Rs 15 crore. 2006 - The company had completed the technology transfer for synthesis of iminostilbenes, an intermediate widely used in different tricycle anti-depressants, to Changshu Wanxing Chemical Company of China. 2007 - Board of directors of the company on 27th October 2007 had accepted resignation letter of Dr. R K Dhar from the directorship as well as CEO of the company, with immediate effect. -Mr. Rajesh Sharma was appointed as additional director of the company. 2008 - Board of directors of the company had approved to issue 14,00,000 warrants, as 8,00,000 warrants to the promoters and to the person acting in concert and 6,00,000 warrants to the persons other than the promoters. 2009 -Company has splits its Face value of Shares from Rs 10 to Re 1 2012 -Company has Consolidates its Face value of Shares from Rs 1 to Rs 10 2013 -Zyden Gentec Ltd has informed that Mr. Manish Jatia has been appointed as an Additional Independent Director on the Board of the Company. 2014 -Zyden Gentec Ltd has informed BSE that Mr. G P Nagar appointed as Compliance Officer of the Company. 2015 -Zyden Gentec Ltd has splits its face values of share from Rs. 10 to Rs. 2
1994 - The company was incorporated as a manufacturer of natural products and chemicals. 2004 - Members at the annual general meeting of the company had approved the increase in authorized share capital from Rs 4.5 crore to 7.5 crore. - The company had an agreement of understanding (AOU) with Zhejiang Hisun Pharmaceuticals Company Ltd. of China in the field of development and sales of anti cancer compounds, their intermediates and penultimates. 2005 - The company had signed an agreement of cooperation and agency with Allessa Chemie of Germany. - The company had planned to raise USD25 million through the issue of Foreign Currency Convertible Bonds (FCCBs). - The company had authorized its board to borrow up to Rs 250 crore. - The company had increased its authorized share capital from Rs 7.5 crore to Rs 15 crore. 2006 - The company had completed the technology transfer for synthesis of iminostilbenes, an intermediate widely used in different tricycle anti-depressants, to Changshu Wanxing Chemical Company of China. 2007 - Board of directors of the company on 27th October 2007 had accepted resignation letter of Dr. R K Dhar from the directorship as well as CEO of the company, with immediate effect. -Mr. Rajesh Sharma was appointed as additional director of the company. 2008 - Board of directors of the company had approved to issue 14,00,000 warrants, as 8,00,000 warrants to the promoters and to the person acting in concert and 6,00,000 warrants to the persons other than the promoters. 2009 -Company has splits its Face value of Shares from Rs 10 to Re 1 2012 -Company has Consolidates its Face value of Shares from Rs 1 to Rs 10 2013 -Zyden Gentec Ltd has informed that Mr. Manish Jatia has been appointed as an Additional Independent Director on the Board of the Company. 2014 -Zyden Gentec Ltd has informed BSE that Mr. G P Nagar appointed as Compliance Officer of the Company. 2015 -Zyden Gentec Ltd has splits its face values of share from Rs. 10 to Rs. 2
Read More
Parent Organisation
Zyden Gentec Ltd.
Founded
26/04/1994
Managing Director
Mr.Vinod Kumar Gupta
NSE Symbol
FAQ
The current price of Zyden Gentec Ltd is
The 52-week high for Zyden Gentec Ltd is
The market capitalization of Zyden Gentec Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Zyden Gentec Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Zyden Gentec Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Zyden Gentec Ltd shares.
The CEO of Zyden Gentec Ltd is Mr.Vinod Kumar Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
